Page results
-
This information aims to answer your questions about a robotic prostatectomy.
-
Occupational therapists support people to do activities which are important to them, but which may be difficult because of health conditions.
-
Digital accessibility and sustainability drive a switch to online patient information at UCLH
-
The rhinology unit covers all aspects of nose and sinus disease including allergy, infection, inflammatory/mucosal conditions, breathing disorders and tumours.
-
The Dermatology Department at University College Hospital is located in the Mortimer Market Centre and is housed in a newly refurbished dedicated skin clinic area where we see all of our adult patients for their outpatient appointments as well as surgical procedures and phototherapy.
-
The FGM service provides consultations, assessments, and support and referral to other services where clinically indicated
-
Online form for beginning the sefl referral process at UCLH maternity services.
-
This page provides information for patients visiting the Inflammatory Bowel Disease clinic.
-
This information outlines the things that you need to take home after your robotic prostatectomy.
-
Overview of the UCLH ambulatory care service for adults with cancer. This service allows people to have their cancer treatment at outpatient appointments, without needing to stay overnight in hospital.
File results
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer